Open Clinical Trials:
CLINICAL TRIAL 18989
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 19327
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases
Disease Site: Non small cell lung cancer, Brain and Nervous System, Lung, Melanoma, skin, Gliomas
View Trial DetailsCLINICAL TRIAL 19441
Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 19495
A Multicenter, Randomized, Double Blinded, Placebo Controlled, Phase 3 trial of Adjuvant Avelumab (anti PDL1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases
Disease Site: Other Skin, Merkel cell carcinoma
View Trial DetailsCLINICAL TRIAL 19748
Phase II Randomized Trial of Radiotherapy with Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients with Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN Trial)
Disease Site: Head & Neck, Squamous Cell Carcinoma (SCC), Lip, Oral Cavity and Pharynx, Other Skin
View Trial DetailsCLINICAL TRIAL 19868
First in Human Phase I Study of 225Actinium-DOTA-Ahx-MC1RL (225Ac-MTI-201) in Metastatic Melanoma
Disease Site: Eye and Orbit, Melanoma, skin
View Trial DetailsCLINICAL TRIAL 19967
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma
Disease Site: Skin, Other Skin
View Trial DetailsCLINICAL TRIAL 20040
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Disease Site: Other Skin, Merkel cell carcinoma
View Trial DetailsCLINICAL TRIAL 20270
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors (IOV-COM-202)
Disease Site: Lung, Melanoma, skin, Non small cell lung cancer
View Trial DetailsCLINICAL TRIAL 20313
Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 20490
Keystroke: A Randomized Phase II Study of Pembrolizumab (Keytruda) Plus Stereotactic Re-irradiation versus SBRT Alone For Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Disease Site: Other Skin
View Trial DetailsCLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 20641
A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 20731
Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Disease Site: Other Skin, Squamous Cell Carcinoma (SCC)
View Trial DetailsCLINICAL TRIAL 20773
Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
Disease Site: Other Skin, Merkel cell carcinoma
View Trial DetailsCLINICAL TRIAL 20794
Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis
Disease Site: Other Skin
View Trial DetailsCLINICAL TRIAL 20854
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Disease Site: Melanoma, skin, Other Skin
View Trial DetailsCLINICAL TRIAL 20904
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in Braf-V600 Mutant Melanoma with Brain Metastases
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 20955
A Phase II Study of Binimetinib plus Belinostat for Subjects with Metastatic Uveal Melanoma
Disease Site: Other Skin
View Trial DetailsCLINICAL TRIAL 20956
A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy Of PF-07284890 (ARRY-461) In Participants With BRAF V600-Mutant Solid Tumors With And Without Brain Involvement
Disease Site: Any Site, Brain and Nervous System, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Skin, Brain metastasis, Gliomas
View Trial DetailsCLINICAL TRIAL 21080
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (DRAGON)
Disease Site: Any Site, Lung, Melanoma, skin, Urinary Bladder
View Trial DetailsCLINICAL TRIAL 21112
Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21163
A Phase 1/2 Study of Regn7075 (Egfrxcd28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Disease Site: Anus, Breast, Cervix, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Lung, Other Digestive Organ, Other Female Genital, Other Male Genital, Other Skin, Other Urinary, Pancreas, Prostate, Stomach
View Trial DetailsCLINICAL TRIAL 21179
A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects with Advanced Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21180
A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)
Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder
View Trial DetailsCLINICAL TRIAL 21239
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21344
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma)
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21553
A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 21573
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients with Hepatic Dominant Ocular Melanoma
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 90015
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
Disease Site: Breast, Lung, Melanoma, skin, Ovary, Pancreas, Urinary Bladder
View Trial DetailsCLINICAL TRIAL 20256
CemiplimAb Survivorship Epidemiology (CASE) Study
Disease Site: Squamous Cell Carcinoma (SCC), Other Skin
View Trial DetailsCLINICAL TRIAL 19950
Linking the Skin and Gut Microbiome to Immunosuppression in Skin Cancer
Disease Site: Other Skin
View Trial DetailsCLINICAL TRIAL 21125
MElanoma Research Lymph Node Prediction Implementation National_001 (MERLIN_001)
Disease Site: Melanoma, skin
View Trial DetailsCLINICAL TRIAL 50401
Creation of Cell Lines and Corresponding DNA and RNA Analysis from Acral Lentiginous Malignant Melanoma
Disease Site: Melanoma, skin
View Trial Details